ABSTRACT
Biological medications are effective for the treatment of cancer and inflammatory diseases. The aim of this review is to summarize the available evidence in systematic reviews or meta-analyses about the risk of infection in patients with cancer, arthritis, psoriasis and inflammatory bowel disease who use biological medications. We included systematic reviews or meta-analyses of controlled clinical trials and case/control studies that analyze infections during and after treatment with FDA-approved biological medications for the treatment of cancer, arthritis, inflammatory bowel disease and psoriasis, both in adults and children. The following databases were consulted: PubMed, Epistemonikos, Crochrane reviews, JIB, and Prospero. A quality guideline (AMSTAR) was applied to the selected studies. We included 26 studies. The risk of infections in patients with solid organ cancer is consistent in the literature. In psoriasis there is a risk of non-serious infections. In arthritis and other inflammatory diseases there is a risk of serious infections. In inflammatory bowel disease there is a risk for opportunistic infections. In conclusion, in patients with cancer and inflammatory diseases use biological medications entails a risk of infection. The evidence is different depending on the underlying disease of each patient.
Subject(s)
Adult , Child , Humans , Psoriasis , Biological Therapy , Inflammatory Bowel Diseases , Infections , Neoplasms , Psoriasis/drug therapy , Biological Therapy/adverse effects , Inflammatory Bowel Diseases/drug therapy , Case-Control Studies , Meta-Analysis as Topic , Risk , Systematic Reviews as Topic , Infections/chemically induced , Neoplasms/drug therapyABSTRACT
In the last years, stem cells have drawn the attention of various sectors of society for many reasons. From the basic point of view, stem cells represent an ideal model to study cell differentiation and self-renewal mechanisms. However, their potential in cell therapy and regenerative medicine has triggered the increasing amount of knowledge in this area. Mesenchymal stem cells belong to the select group of adult stem cells. They have differentiation potential towards mesenchymal tissues such as bone, cartilage, stroma and fat. Recently, both in vivo and in vitro reports have shown a greater plasticity of mesenchymal stem cells, showing not only a mesenchymal cell fate but also those leading to endothelial, nervous and muscular lineages. For these reasons, the study of mesenchymal stem cells has gained great interest and many articles have been published. In the present review, we have presented a global vision of this topic, including its history, biologic features, sources, isolation methods and an overview on their clinical application.
En los últimos años, el tema de las células troncales o células madre ha llamado la atención a varios sectores de la sociedad por diversas razones. Desde el punto de vista básico, constituyen un inmejorable modelo para estudiar los mecanismos de diferenciación y autorrenovación celular. Sin embargo, es sin duda, su potencial en la terapia celular y la medicina regenerativa lo que ha disparado la generación de estudios y conocimientos sobre este tema. Las células troncales mesenquimales pertenecen al selecto grupo de células troncales de tejido adulto. Poseen un gran potencial de diferenciación a diversos tejidos mesenquimales, como hueso, cartílago, estroma y tejido graso. Reportes recientes, tanto in vitro como in vivo han demostrado una mayor plasticidad celular, ya que son capaces de originar células endoteliales, musculares e incluso células neuronales. Es por esto que el estudio de las células troncales mesenquimales ha cobrado un gran interés y ha generado una gran cantidad de información. En este trabajo de revisión se presenta una visión global sobre ellas, abarcando su historia, métodos de obtención, características biológicas, fuentes de obtención y aplicación clínica.
Subject(s)
Animals , Humans , Mesenchymal Stem Cell Transplantation , Mesenchymal Stem CellsABSTRACT
During the last 20 years, several concepts regarding the biology of acute myeloid leukemia (AML) have changed in a profound manner. This has been mainly due to significant advances in the identification, purification and characterization of the primitive hematopoietic cells--including stem and progenitor cells--in which this disorder originates. In the present review article, we discuss some of these new concepts and their relevance in the treatment of AML.
Subject(s)
Humans , Leukemia, Myeloid, Acute , /biosynthesis , Hematopoiesis , Leukemia, Myeloid, AcuteABSTRACT
En este trbajo se evaluó si el factor estimulador de colonias de macrófagos y granulocitos (GM-CSF) tiene al marcófago como única célula clanca. Para ello, se determinó la cinética de respuesta de precurores mieloides al GM-CSF en cultivos semisólidos. Los macrófagos son capaces de secretar el estimuladora de granulocitos (G-CSF), por tanto también se evaluó la posible secreción de G-CSF por los macrófagos inducidos con GM-CSF, Nuestros resultados indican que únicamente los precursores de macrófagos responden en forma temprana al GM_CSF, ya que al resembrar los grupos generados a los dos días se originan exclusivamente colonias de macrófago. Por otro lado el lisado de estas colonias promueve principalmente la formación de colinias granulocíticas. Finalmente se discute la posibilidad de que el GM-CSF sean en realidad un estimulador de macrófagos con capacidad de inducir la secreció de G-CSF, así como de la posible inexistencia de un precursor común demacrófagos y garnulocitos.